SUBSCRIBE

Zelboraf

FDA approves new melanoma drug

The U.S. Food and Drug Administration (FDA) has approved Zelboraf (vemurafenib) for use in patients with metastatic or unresectable melanoma who have the BRAF V600E mutation. Read more.

Reader Survey

Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.

Survey
cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Poll

319822 359374